Rethinking Alzheimer's Trial Recruitment And Why It Can't Wait

By Joanna Pulawska, PhD, Therapeutic Area Head, CNS, IQVIA Biotech

Alzheimer’s disease trials face one of the most pressing challenges in clinical research: patient recruitment. With prevalence rising and therapeutic innovation accelerating, delays in enrollment can derail timelines and increase costs dramatically.

Traditional recruitment models often fail to address the complexity of Alzheimer’s studies, which require highly specific eligibility criteria, caregiver involvement, and long-term commitment. To overcome these hurdles, sponsors must adopt proactive strategies that leverage real-world data, predictive analytics, and community-based outreach to identify and engage qualified participants earlier. Incorporating decentralized trial elements and digital tools can further reduce patient burden and improve retention.

The urgency is clear — every delay impacts not only development milestones but also patients waiting for new treatment options. Access the full resource to explore innovative approaches that can transform Alzheimer’s trial recruitment and accelerate progress for this critical therapeutic area.